Stocktoria
ImageneBio, Inc. IMA
ImageneBio, Inc. (IMA) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $800,000 at a -5668.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.844 |
| Retained earnings / assets | -1.504 |
| EBIT / assets | -0.317 |
| Equity / liabilities | 6.712 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IMA | ImageneBio, Inc. | 3/9 | 5.55 | — | — |
| PROK | PROKIDNEY CORP. | 1/9 | — | — | — |
| CRDF | Cardiff Oncology, Inc. | 2/9 | — | — | — |
| SCNI | Scinai Immunotherapeutics Ltd. | 2/9 | — | — | — |
| PLUR | Pluri Inc. | 2/9 | — | — | — |
| ATYR | aTYR PHARMA INC | 1/9 | -19.49 | — | — |
| OTLK | Outlook Therapeutics, Inc. | 1/9 | — | — | — |
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
FAQ
Is IMA financially healthy?
ImageneBio, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does IMA pay a dividend?
No, ImageneBio, Inc. does not currently pay a dividend.
How profitable is IMA?
In FY2025, ImageneBio, Inc. had a net margin of -5668.6% and a return on equity of -34.1%.
What is the analyst price target for IMA?
The average Wall-Street price target for ImageneBio, Inc. is $24.00, about 300.7% above the recent price, from 1 analysts.
Is IMA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ImageneBio, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.